NASDAQ:ESPR
Esperion Therapeutics Stock News
$2.36
-0.230 (-8.88%)
At Close: May 17, 2024
Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®
08:00am, Tuesday, 14'th May 2024
ANN ARBOR, Mich., May 14, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) announced today that the U.S. Patent and Trademark Office (USPTO) issued a U.S. Patent Term Extension (PTE) certificate for b
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04:00pm, Friday, 10'th May 2024
ANN ARBOR, Mich., May 10, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on May 8, 2024, the Company granted 16 new employees 62,300 restricted stock units (RSUs) under Esperion
Esperion (ESPR) Q1 Earnings Beat, Stock Up on Strong Revenues
01:20pm, Wednesday, 08'th May 2024
Esperion's (ESPR) first-quarter earnings and sales beat estimates on the back of better-than-expected collaboration revenues.
Why Is Esperion Therapeutics (ESPR) Stock Up 13% Today?
08:22am, Tuesday, 07'th May 2024
Esperion Therapeutics (NASDAQ: ESPR ) stock is up on Tuesday after the pharmaceutical company released its earnings report for the first quarter of 2024. The good news from this earnings report inclu
Esperion Therapeutics (ESPR) Q1 Earnings and Revenues Beat Estimates
08:16am, Tuesday, 07'th May 2024
Esperion Therapeutics (ESPR) came out with quarterly earnings of $0.34 per share, beating the Zacks Consensus Estimate of a loss of $0.08 per share. This compares to loss of $0.79 per share a year ago
Esperion Reports First Quarter 2024 Financial Results
06:00am, Tuesday, 07'th May 2024
– Q1 Total Revenue Grew 467% Y/Y to $137.7 Million, Reflecting Strong Growth Globally – – Q1 U.S. Net Product Revenue Grew 46% Y/Y to $24.8 Million – – Q1 Retail Prescription Equivalents Gre
Esperion to Participate in Upcoming May Investor Conferences
08:00am, Monday, 29'th Apr 2024
ANN ARBOR, Mich., April 29, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the following webcasted investor events during the month of May,
– Patients With Obesity Who Took NEXLETOL Were 23% Less Likely to Experience a Major Adverse Cardiovascular Event (MACE-4) Compared to Placebo –
Esperion Therapeutics (ESPR) CEO on Cholesterol Lowering Medications
12:48pm, Monday, 01'st Apr 2024
Esperion Therapeutics (ESPR) specializes in cholesterol lowering medications. President and CEO Sheldon Koenig joins Nicole Petallides to give an overview of the company.
Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024
08:00am, Monday, 01'st Apr 2024
ANN ARBOR, Mich., April 01, 2024 (GLOBE NEWSWIRE) -- Esperion (Nasdaq: ESPR) today announced that Sheldon Koenig, President and CEO, will ring the Nasdaq Stock Market (Nasdaq) opening bell at 9:30 a.m
Why Is Esperion Therapeutics (ESPR) Up 2% Since Last Earnings Report?
12:36pm, Thursday, 28'th Mar 2024
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock?
Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference
08:00am, Tuesday, 26'th Mar 2024
ANN ARBOR, Mich., March 26, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced its participation in the 23rd Annual Needham Virtual Healthcare Conference. Sheldon Koenig, President and C
ANN ARBOR, Mich., March 25, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the acceptance of three CLEAR ( C holesterol L owering via B e mpedoic acid, an A CL-Inhibiting R egimen)
ANN ARBOR, Mich.--(BUSINESS WIRE)--Esperion (NASDAQ: ESPR) today announced that the United States Food and Drug Administration (FDA) has approved broad new label expansions for NEXLETOL® (bempedoic a
– New Labels Expand Treatable Population to ~70 Million Patients in U.S. – – First LDL-C Lowering Non-Statin Indicated for Primary Prevention Patients – – Approvals Based on Positive CLEAR O
